Special Issue "Advances in Multiple Sclerosis 2016"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (30 September 2016).
Prof. Dr. Christoph Kleinschnitz
Universitätsklinikum Essen (AöR), Klinik für Neurologie, Hufelandstraße 55, D-45147 Essen, Germany
Website | E-Mail
Interests: neuroimmunology; emphasis on Multiple Sclerosis; stroke (experimental/clinical); thromboinflammation; immune system/inflammation; neuroprotection; cellular and molecular neuroimaging by magnetic resonance imaging
Study of Multiple Sclerosis (MS) is one of the most exciting, emerging fields in neurology. Recent pathophysiological insights, derived from both animal models and clinical studies, paved the way for the regulatory approval of novel MS treatments, most recently the novel B-cell depleting antibody ocrelizumab showed promising results in phase III trials in relapsing-remitting (RRMS) and primary progressive MS (PPMS). Some of these compounds possibly act beyond their well-established immunomodulatory properties, for instance, by inducing direct neuroprotection or neuroregeneration (e.g., Anti-LINGO-1). Of note, even childhood MS has been recognized as a significant medical problem demonstrating axonal degeneration early in the disease course and novel therapies are increasingly tested for this population. However, important, unmet medical needs remain and the quest for even more sophisticated treatment strategies continues. For example, promising preclinical data exist regarding the modulation of certain ion channels expressed on immune cells, B cell function in PPMS, and the functional state of the blood-brain-barrier. Additionally, the search for novel biomarkers predicting treatment responses and/or disease progression is ongoing. Improved imaging techniques, such as diffusion tensor imaging or optical coherence tomography, have helped gain in vivo insights into the pathophysiological processes directly acting in MS patients.
The upcoming Special Issue on "Advances in Multiple Sclerosis" will cover all aspects of this most prevalent neuroimmunological disease. We invite authors to submit original articles or state-of-the art reviews on MS pathophysiology, therapy, epidemiology, environmental factors, and imaging. All contributions will undergo a rapid, fair, and concise review process to minimize publication times.
We look forward to receiving your valuable submissions.
Prof. Christoph Kleinschnitz
Prof. Sven Meuth
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Multiple Sclerosis
- environmental factors